About belzutifan
Hypoxia-inducible factor-2 alpha inhibitor
Used for
- Treats adults with von Hippel-Lindau disease needing treatment for associated tumors.
- Treats advanced renal cell carcinoma after prior therapies.
- Treats certain advanced pheochromocytomas or paragangliomas.
Usual adult dose
120 mg by mouth once daily for adults; dose may be reduced for side effects.
Common side effects
- Anemia
- Fatigue
- Headache
- Dizziness
Important warnings
- Can cause severe anemia and require blood transfusions.
- May cause low blood oxygen levels; monitor for breathing problems.
- Can harm an unborn baby; use effective contraception during treatment and afterward.
- May reduce effectiveness of hormonal contraceptives.
Pregnancy
Can cause fetal harm; pregnancy testing and effective contraception are recommended during treatment and for one week afterward.
Breastfeeding
Do not breastfeed during treatment and for one week after the last dose.
Interactions
- May reduce effectiveness of hormonal contraceptives.
- May interact with sensitive CYP3A4 substrates; medication review may be needed.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.